[go: up one dir, main page]

MC2324A1 - Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone - Google Patents

Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone

Info

Publication number
MC2324A1
MC2324A1 MC912324A MC2324A MC2324A1 MC 2324 A1 MC2324 A1 MC 2324A1 MC 912324 A MC912324 A MC 912324A MC 2324 A MC2324 A MC 2324A MC 2324 A1 MC2324 A1 MC 2324A1
Authority
MC
Monaco
Prior art keywords
interactions
inhibition
cell adhesive
adhesive proteins
carbon hydrates
Prior art date
Application number
MC912324A
Other languages
English (en)
French (fr)
Inventor
Seed Brian Mm
Gerd Walz
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of MC2324A1 publication Critical patent/MC2324A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MC912324A 1990-11-23 1991-11-18 Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone MC2324A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61831490A 1990-11-23 1990-11-23

Publications (1)

Publication Number Publication Date
MC2324A1 true MC2324A1 (fr) 1994-01-18

Family

ID=24477202

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912324A MC2324A1 (fr) 1990-11-23 1991-11-18 Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone

Country Status (16)

Country Link
US (5) US5801044A (no)
EP (1) EP0640129A1 (no)
JP (2) JPH06504619A (no)
AU (1) AU656934B2 (no)
BR (1) BR9106995A (no)
CA (1) CA2097617A1 (no)
CZ (1) CZ96893A3 (no)
FI (1) FI932336L (no)
HU (1) HUT64476A (no)
IE (1) IE914075A1 (no)
IL (1) IL100094A0 (no)
MC (1) MC2324A1 (no)
NO (1) NO931864L (no)
NZ (1) NZ240646A (no)
PT (1) PT99582A (no)
WO (1) WO1992009293A1 (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391857B1 (en) * 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) * 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
AU656934B2 (en) * 1990-11-23 1995-02-23 General Hospital Corporation, The Inhibition of cell adhesion protein-carbohydrate interactions
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
EP0521692A3 (en) * 1991-07-02 1993-02-03 The Biomembrane Institute Inhibition of tumor cell metastasis potential and invasiveness by chemically-defined oligosaccharides, their derivatives, mimetics and antibodies directed to them
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
AU686116B2 (en) 1992-10-02 1998-02-05 Alberta Research Council Inc. Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
WO1999060113A1 (fr) * 1998-05-20 1999-11-25 Chugai Seiyaku Kabushiki Kaisha Nouveau procede d'isolation de gene
EP2275541B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2003025133A2 (en) * 2001-09-14 2003-03-27 Mimeon, Inc. Methods of making glycolmolecules with enhanced activities and uses thereof
AU2002340168A1 (en) * 2001-10-11 2003-06-17 Protein Design Labs Inc. Treatment of prostate cancer by inhibitors of ncam2
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
AU2003249641B2 (en) * 2002-05-16 2009-08-20 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
CA2490703A1 (en) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
AU2004280064A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell neutralized to serum-free system
US7691810B2 (en) * 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
EP1763533B1 (en) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Specific antagonist for both e- and p-selectins
WO2005054264A2 (en) * 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
DK1928892T3 (da) * 2005-08-09 2012-01-30 Glycomimetics Inc Glycomimetiske inhibitorer af PA-IL-lectin PA-IIL-lectin eller begge lectiner fra pseudomonas
DK2264043T3 (da) 2005-09-02 2018-01-29 Glycomimetics Inc Heterobifunktionelle pan-selektin-inhibitorer
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1957099B1 (en) * 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
WO2007112403A2 (en) * 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
EP2010566B2 (en) * 2006-04-05 2017-07-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
US7964569B2 (en) 2006-10-12 2011-06-21 Glycomimetics, Inc. Glycomimetic replacements for hexoses and N-acetyl hexosamines
EP2117561A1 (en) * 2007-02-09 2009-11-18 GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
CA2722173A1 (en) * 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
CA2727788A1 (en) * 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
JP5726171B2 (ja) * 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
CN101921336B (zh) * 2009-06-11 2013-02-27 北京华大蛋白质研发中心有限公司 一种抗人α1酸性糖蛋白的单克隆抗体及其制备方法
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
WO2011149999A2 (en) 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
WO2012125553A2 (en) 2011-03-12 2012-09-20 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing n-glycans in glycoprotein products
WO2012162277A1 (en) 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
EP2856159A4 (en) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS RELATING TO DENOSUMAB
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
DK3227310T3 (da) 2014-12-03 2019-09-30 Glycomimetics Inc Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
EP3405473A1 (en) 2016-01-22 2018-11-28 GlycoMimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN109890421B (zh) 2016-10-07 2023-10-20 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7449390B2 (ja) 2020-01-24 2024-03-13 ファイザー・インク 抗ｅ－セレクチン抗体、組成物および使用の方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
DE2621908A1 (de) * 1975-05-26 1976-12-09 Sandoz Ag Neues diagnostikum fuer maligne tumore
JPS53136586A (en) * 1977-05-02 1978-11-29 Ajinomoto Co Inc Preparation of llglutamic acidd*c* semialdehyde
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60123494A (ja) * 1983-12-08 1985-07-02 Rikagaku Kenkyusho シアル酸含有オリゴ糖およびその製造法
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
JPS6283898A (ja) * 1985-10-09 1987-04-17 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺腺癌特異的単クロ−ン性抗体
US4851511A (en) * 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
EP0323802A3 (en) * 1987-12-24 1989-07-26 Sandoz Ag Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
WO1989008711A1 (en) * 1988-03-11 1989-09-21 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
ATE142505T1 (de) * 1988-11-14 1996-09-15 Brigham & Womens Hospital Antikörper, spezifisch gegen elam-1 sowie deren verwendung
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
FR2654876B1 (fr) * 1989-11-23 1993-11-12 Commissariat A Energie Atomique Dispositif de charge de moyens d'accumulation d'energie electrique, muni de moyens permettant de maitriser cette charge.
WO1991016900A1 (en) * 1990-04-27 1991-11-14 Biogen, Inc. Fucosyl transferases involved in adhesion molecule expression
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5211936A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a cite of inflammation utilizing elam-1 ligands site
AU656934B2 (en) * 1990-11-23 1995-02-23 General Hospital Corporation, The Inhibition of cell adhesion protein-carbohydrate interactions
DE69233654D1 (de) * 1991-04-19 2006-10-19 Univ Leland Stanford Junior Zusammensetzungen und methoden für die verknüpfung von endothelzellen
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates

Also Published As

Publication number Publication date
US6613746B1 (en) 2003-09-02
IE914075A1 (en) 1992-06-03
HU9301510D0 (en) 1993-10-28
US5801044A (en) 1998-09-01
NZ240646A (en) 1994-01-26
EP0640129A1 (en) 1995-03-01
CZ96893A3 (en) 1993-12-15
AU9061891A (en) 1992-06-25
CA2097617A1 (en) 1992-05-23
AU656934B2 (en) 1995-02-23
PT99582A (pt) 1992-10-30
US5858983A (en) 1999-01-12
EP0640129A4 (en) 1994-07-05
NO931864D0 (no) 1993-05-21
NO931864L (no) 1993-07-21
FI932336A0 (fi) 1993-05-21
US6156881A (en) 2000-12-05
JPH06504619A (ja) 1994-05-26
WO1992009293A1 (en) 1992-06-11
HUT64476A (en) 1994-01-28
FI932336L (fi) 1993-05-21
BR9106995A (pt) 1993-08-24
IL100094A0 (en) 1992-08-18
JP2000325092A (ja) 2000-11-28
US5723583A (en) 1998-03-03

Similar Documents

Publication Publication Date Title
MC2324A1 (fr) Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone
FR2617712B1 (fr) Substance inhibitrice du developpement cellulaire dite dolastatine 10
AU588220B2 (en) Improved expression vector and use thereof
BR8803135A (pt) Composicao consolidavel e material refratario
DE69505257D1 (de) Elektrochemische oxydation von materialien
TR23107A (tr) Sert pvc'den mamuel doekuem parcalarinin yapistinlmasina mahsus madde
DE69333921D1 (de) "enhancer" sequenz zur modulation der expression in epithelialzellen
FR2611142B1 (fr) Poche d'ostomie
AU8094682A (en) Bacillus thuringiensis mutant and insecticide based thereon
FR2577141B1 (fr) Protection des hydrocarbures contre l'action de microorganismes
AU7284787A (en) Copy and material holder
NO170811C (no) Oxydasjons- og varmemotstandsdyktig sammensatt gjenstand og legeringsmateriale
AU8073391A (en) Clip providing improved storage and handling of flexible bags
DK227985A (da) Kloning og karakterisering af det humane interleukin 1 gen
NO932260D0 (no) Tape eller ark av komposittmateriale, samt anvendelse derav
DE69324812D1 (de) Zellaktivator des eingeweidetraktes
DE3279565D1 (en) Salts of amino organic peroxides and uses thereof
FR2740472B1 (fr) Nouvelles souches de bacillus thuringiensis et composition pesticide les contenant
AU8193391A (en) Photobioreactors and closed ecological life support systems and artificial lungs containing the same
BR8901182A (pt) Suspensao aquosa estavel e utilizacao desta suspensao
IL90184A0 (en) Functionalized peptidyl aminodiols and-triols
FR2560582B1 (fr) Recipient portatif non reutilisable
IT1175825B (it) Dispersione adesiva reattiva e procedimento d'impiego
CS4488A1 (en) Diagram of characteristics' group linearization and scaling
FR2615447B1 (fr) Feuille composite pour le revetement etanche d'elements de construction et procedes pour sa realisation